Brugada Syndrome: Clinical, Genetic, Molecular, Cellular, and Ionic Aspects

Current Problems in Cardiology

Volumn 41, Issue 1, 2016, Pages 7-57

  Antzelevitch, Charles ^a   Patocskai, Bence ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BRUGADA SYNDROME; CARDIOLOGIST; CLINICAL STUDY; ELECTROPHYSIOLOGY; HUMAN; SCIENCE; ARRHYTHMIAS, CARDIAC; ELECTROCARDIOGRAPHY; GENETIC PREDISPOSITION; GENETICS; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MUTATION; RISK FACTOR;

CALCIUM CHANNEL; SODIUM CHANNEL;

ARRHYTHMIAS, CARDIAC; BRUGADA SYNDROME; CALCIUM CHANNELS; DEFIBRILLATORS, IMPLANTABLE; ELECTROCARDIOGRAPHY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; RISK FACTORS; SODIUM CHANNELS;

EID: 84949728727     PISSN: 01462806     EISSN: 15356280     Source Type: Journal    
DOI: 10.1016/j.cpcardiol.2015.06.002     Document Type: Article

References (285)

1. Hermida J.S., Lemoine J.L., Aoun F.B., Jarry G., Rey J.L., Quiret J.C. Prevalence of the Brugada syndrome in an apparently healthy population. Am J Cardiol 2000, 86:91-94.
2. Postema P.G. About Brugada syndrome and its prevalence. Europace 2012, 14:925-928.
3. Patel S.S., Anees S.S., Ferrick K.J. Prevalence of a Brugada pattern electrocardiogram in an urban population in the United States. Pacing Clin Electrophysiol 2009, 32:704-708.
4. Pecini R., Cedergreen P., Theilade S., Haunso S., Theilade J., Jensen G.B. The prevalence and relevance of the Brugada-type electrocardiogram in the Danish general population: data from the Copenhagen City Heart Study. Europace 1907, 12:982-986.
5. Sinner M.F., Pfeufer A., Perz S., et al. Spontaneous Brugada electrocardiogram patterns are rare in the German general population: results from the KORA study. Europace 2009, 11:1338-1344.
6. Schukro C., Berger T., Stix G., et al. Regional prevalence and clinical benefit of implantable cardioverter defibrillators in Brugada syndrome. Int J Cardiol 2010, 144:191-194.
7. Tsuji H., Sato T., Morisaki K., Iwasaka T. Prognosis of subjects with Brugada-type electrocardiogram in a population of middle-aged Japanese diagnosed during a health examination. Am J Cardiol 2008, 102:584-587.
8. Uhm J.S., Hwang I.U., Oh Y.S., et al. Prevalence of electrocardiographic findings suggestive of sudden cardiac death risk in 10,867 apparently healthy young Korean men. Pacing Clin Electrophysiol 2011, 34:717-723.
9. Juang J.M., Phan W.L., Chen P.C., et al. Brugada-type electrocardiogram in the Taiwanese population--is it a risk factor for sudden death?. J Formos Med Assoc 2011, 110:230-238.
10. Letsas K.P., Gavrielatos G., Efremidis M., et al. Prevalence of Brugada sign in a Greek tertiary hospital population. Europace 2007, 9:1077-1080.
11. Matsuo K., Akahoshi M., Nakashima E., et al. The prevalence, incidence and prognostic value of the Brugada-type electrocardiogram: a population-based study of four decades. J Am Coll Cardiol 2001, 38:765-770.
12. Furuhashi M., Uno K., Tsuchihashi K., et al. Prevalence of asymptomatic ST segment elevation in right precordial leads with right bundle branch block (Brugada-type ST shift) among the general Japanese population. Heart 2001, 86:161-166.
13. Gervacio-Domingo G., Isidro J., Tirona J., et al. The Brugada type 1 electrocardiographic pattern is common among Filipinos. J Clin Epidemiol 2008, 61:1067-1072.
14. Gallagher M.M., Forleo G.B., Behr E.R., et al. Prevalence and significance of Brugada-type ECG in 12,012 apparently healthy European subjects. Int J Cardiol 2008, 130:44-48.
15. Junttila M.J., Raatikainen M.J., Karjalainen J., Kauma H., Kesaniemi Y.A., Huikuri H.V. Prevalence and prognosis of subjects with Brugada-type ECG pattern in a young and middle-aged Finnish population. Eur Heart J 2004, 25:874-878.
16. Ito H., Yano K., Chen R., He Q., Curb J.D. The prevalence and prognosis of a Brugada-type electrocardiogram in a population of middle-aged Japanese-American men with follow-up of three decades. Am J Med Sci 2006, 331:25-29.
17. Donohue D., Tehrani F., Jamehdor R., Lam C., Movahed M.R. The prevalence of Brugada ECG in adult patients in a large university hospital in the western United States. Am Heart Hosp J 2008, 6:48-50.
18. Bozkurt A., Yas D., Seydaoglu G., Acarturk E. Frequency of Brugada-type ECG pattern (Brugada sign) in Southern Turkey. Int Heart J 2006, 47:541-547.
19. Bigi M.A., Aslani A., Shahrzad S. Prevalence of Brugada sign in patients presenting with palpitation in southern Iran. Europace 2007, 9:252-255.
20. Greer R.W., Glancy D.L. Prevalence of the Brugada electrocardiographic pattern at the Medical Center of Louisiana in New Orleans. J La State Med Soc 2003, 155:242-246.
21. Sakabe M., Fujiki A., Tani M., Nishida K., Mizumaki K., Inoue H. Proportion and prognosis of healthy people with coved or saddle-back type ST segment elevation in the right precordial leads during 10 years follow-up. Eur Heart J 2003, 24:1488-1493.
22. Wajed A., Aslam Z., Abbas S.F., et al. Frequency of Brugada-type ECG pattern (Brugada sign) in an apparently healthy young population. J Ayub Med Coll Abbottabad 2008, 20:121-124.
23. Nademanee K., Veerakul G., Nimmannit S., et al. Arrhythmogenic marker for the sudden unexplained death syndrome in Thai men. Circulation 1997, 96:2595-2600.
24. Miyasaka Y., Tsuji H., Yamada K., et al. Prevalence and mortality of the Brugada-type electrocardiogram in one city in Japan. J Am Coll Cardiol 2001, 38:771-774.
25. Vatta M., Dumaine R., Varghese G., et al. Genetic and biophysical basis of sudden unexplained nocturnal death syndrome (SUNDS), a disease allelic to Brugada syndrome. Hum Mol Genet 2002, 11:337-345.
26. Eckardt L., Kirchhof P., Johna R., Haverkamp W., Breithardt G., Borggrefe M. Wolff-Parkinson-White syndrome associated with Brugada syndrome. Pacing Clin Electrophysiol 2001, 24:1423-1424.
27. Morita H., Fukushima-Kusano K., Nagase S., et al. Sinus node function in patients with Brugada-type ECG. Circ J 2004, 68:473-476.
28. Takehara N., Makita N., Kawabe J., et al. A cardiac sodium channel mutation identified in Brugada syndrome associated with atrial standstill. J Intern Med 2004, 255:137-142.
29. Bordachar P., Reuter S., Garrigue S., et al. Incidence, clinical implications and prognosis of atrial arrhythmias in Brugada syndrome. Eur Heart J. 2004, 25:879-884.
30. Wilde A.A., Antzelevitch C., Borggrefe M., et al. Proposed diagnostic criteria for the Brugada syndrome. Eur Heart J 2002, 23:1648-1654.
31. Wilde A.A., Antzelevitch C., Borggrefe M., et al. Proposed diagnostic criteria for the Brugada syndrome: consensus report. Circulation 2002, 106:2514-2519.
32. Antzelevitch C., Brugada P., Borggrefe M., et al. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 2005, 111:659-670.
33. Priori S.G., Wilde A.A., Horie M., et al. Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Heart Rhythm 2013, 15:1389-1406.
34. Richter S., Sarkozy A., Paparella G., et al. Number of electrocardiogram leads displaying the diagnostic coved-type pattern in Brugada syndrome: a diagnostic consensus criterion to be revised. Eur Heart J 2010, 31:1357-1364.
35. Antzelevitch C., Brugada P., Borggrefe M., et al. Brugada syndrome: report of the second consensus conference. Heart Rhythm 2005, 2:429-440.
36. Probst V., Veltmann C., Eckardt L., et al. Long-term prognosis of patients diagnosed with Brugada syndrome: results from the FINGER Brugada Syndrome Registry. Circulation 2010, 121:635-643.
37. Brugada R., Brugada J., Antzelevitch C., et al. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation 2000, 101:510-515.
38. Shimizu W., Antzelevitch C., Suyama K., et al. Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol 2000, 11:1320-1329.
39. Hong K., Brugada J., Oliva A., et al. Value of electrocardiographic parameters and ajmaline test in the diagnosis of Brugada syndrome caused by SCN5A mutations. Circulation 2004, 110:3023-3027.
40. Meregalli P.G., Ruijter J.M., Hofman N., Bezzina C.R., Wilde A.A., Tan H.L. Diagnostic value of flecainide testing in unmasking SCN5A-related Brugada syndrome. J Cardiovasc Electrophysiol 2006, 17:857-864.
41. Priori S.G., Napolitano C., Gasparini M., et al. Clinical and genetic heterogeneity of right bundle branch block and ST-segment elevation syndrome: a prospective evaluation of 52 families. Circulation 2000, 102:2509-2515.
42. Gavrielatos G., Letsas K.P., Pappas L.K., Efremidis M., Sideris A., Kardaras F. Sensitivity and specificity of sodium channel blocking test in the diagnosis of Brugada syndrome. Int J Cardiol 2010, 141:e31-e33.
43. Wolpert C., Echternach C., Veltmann C., et al. Intravenous drug challenge using flecainide and ajmaline in patients with Brugada syndrome. Heart Rhythm 2005, 2:254-260.
44. Shimizu W. Acquired forms of Brugada syndrome. The Brugada Syndrome: From Bench to Bedside 2004, 166-177. Oxford, Blackwell Futura, UK. C. Antzelevitch (Ed.).
45. Brugada P., Brugada J., Brugada R. Arrhythmia induction by antiarrhythmic drugs. Pacing Clin Electrophysiol 2000, 23:291-292.
46. Miyazaki T., Mitamura H., Miyoshi S., Soejima K., Aizawa Y., Ogawa S. Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome. J Am Coll Cardiol 1996, 27:1061-1070.
47. Antzelevitch C., Brugada R. Fever and the Brugada syndrome. Pacing Clin Electrophysiol 2002, 25:1537-1539.
48. Peng J., Cui Y.K., Yuan F.H., Yi S.D., Chen Z.M., Meng S.R. Fever and Brugada syndrome: report of 21 cases. Di Yi Jun Yi Da Xue Xue Bao 2005, 25:432-434.
49. Junttila M.J., Gonzalez M., Lizotte E., et al. Induced Brugada-type electrocardiogram, a sign for imminent malignant arrhythmias. Circulation 2008, 117:1890-1893.
50. Adler A., Topaz G., Heller K., et al. Fever-induced Brugada pattern: how common is it and what does it mean?. Heart Rhythm 2013, 10:1375-1382.
51. Shimizu W., Matsuo K., Takagi M., et al. Body surface distribution and response to drugs of ST segment elevation in Brugada syndrome: clinical implication of eighty-seven-lead body surface potential mapping and its application to twelve-lead electrocardiograms. J Cardiovasc Electrophysiol 2000, 11:396-404.
52. Sangwatanaroj S., Prechawat S., Sunsaneewitayakul B., Sitthisook S., Tosukhowong P., Tungsanga K. New electrocardiographic leads and the procainamide test for the detection of the Brugada sign in sudden unexplained death syndrome survivors and their relatives. Eur Heart J 2001, 22:2290-2296.
53. Teijeiro R., Garro H.A., Acunzo R.S., Albino E., Chiale P.A. Recording of high V1-V3 precordial leads may be essential to the diagnosis of Brugada syndrome during the ajmaline test. J Cardiovasc Pharmacol Ther 2006, 11:153-155.
54. Miyamoto K., Yokokawa M., Tanaka K., et al. Diagnostic and prognostic value of a type 1 Brugada electrocardiogram at higher (third or second) V1 to V2 recording in men with Brugada syndrome. Am J Cardiol 2007, 99:53-57.
55. Marquez M.F., Allende R., Morales J.L. Unmasking the Brugada syndrome with high parasternal leads. Europace 2007, 9(12):1216.
56. Govindan M., Batchvarov V.N., Raju H., et al. Utility of high and standard right precordial leads during ajmaline testing for the diagnosis of Brugada syndrome. Heart 2010, 96:1904-1908.
57. Baranchuk A., Nguyen T., Ryu M.H., et al. Brugada phenocopy: new terminology and proposed classification. Ann Noninvasive Electrocardiol 2012, 17:299-314.
58. Bayes de Luna A., Brugada J., Baranchuk A., et al. Current electrocardiographic criteria for diagnosis of Brugada pattern: a consensus report. J Electrocardiol 2012, 45:433-442.
59. Arce M., Riera A.R., Femenia F., Baranchuk A. Brugada electrocardiographic phenocopy in a patient with chronic Chagasic cardiomyopathy. Cardiol J 2010, 17:525-527.
60. Brito M.R., Miranda C.E., Rabelo W., Marino R.L. Type 1 electrocardiographic Brugada pattern in a woman with Chagas disease: a case report. Europace 2010, 12:1345-1346.
61. Garcia-Niebla J., Llontop-Garcia P., Valle-Racero J.I., Serra-Autonell G., Batchvarov V.N., De Luna A.B. Technical mistakes during the acquisition of the electrocardiogram. Ann Noninvasive Electrocardiol 2009, 14:389-403.
62. Garcia-Niebla J., Serra-Autonell G. Effects of inadequate low-pass filter application. J Electrocardiol 2009, 42:303-304.
63. Chiale P.A., Garro H.A., Fernandez P.A., Elizari M.V. High-degree right bundle branch block obscuring the diagnosis of Brugada electrocardiographic pattern. Heart Rhythm 2012, 9:974-976.
64. Aizawa Y., Takatsuki S., Kimura T., et al. Ventricular fibrillation associated with complete right bundle branch block. Heart Rhythm 2013, 10:1028-1035.
65. Chevallier S., Forclaz A., Tenkorang J., et al. New electrocardiographic criteria for discriminating between brugada types 2 and 3 patterns and incomplete right bundle branch block. J Am Coll Cardiol 2011, 58:2290-2298.
66. Corrado D., Pelliccia A., Heidbuchel H., et al. Recommendations for interpretation of 12-lead electrocardiogram in the athlete. Eur Heart J 2010, 31:243-259.
67. Kalla H., Yan G.X., Marinchak R. Ventricular fibrillation in a patient with prominent J (Osborn) waves and ST segment elevation in the inferior electrocardiographic leads: a Brugada syndrome variant?. J Cardiovasc Electrophysiol 2000, 11:95-98.
68. Horigome H., Shigeta O., Kuga K., et al. Ventricular fibrillation during anesthesia in association with J waves in the left precordial leads in a child with coarctation of the aorta. J Electrocardiol 2003, 36:339-343.
69. Potet F., Mabo P., Le Coq G., et al. Novel Brugada SCN5A mutation leading to ST segment elevation in the inferior or the right precordial leads. J Cardiovasc Electrophysiol 2003, 14:200-203.
70. Letsas K.P., Sacher F., Probst V., et al. Prevalence of early repolarization pattern in inferolateral leads in patients with Brugada syndrome. Heart Rhythm 2008, 5:1685-1689.
71. Kawata H., Morita H., Yamada Y., et al. Prognostic significance of early repolarization in inferolateral leads in Brugada patients with documented ventricular fibrillation: a novel risk factor for Brugada syndrome with ventricular fibrillation. Heart Rhythm 2013, 10:1161-1168.
72. Takagi M., Aonuma K., Sekiguchi Y., Yokoyama Y., Aihara N., Hiraoka M. The prognostic value of early repolarization (J wave) and ST-segment morphology after J wave in Brugada syndrome: multicenter study in Japan. Heart Rhythm 2013, 10:533-539.
73. Antzelevitch C., Yan G.X. J wave syndromes. Heart Rhythm 2010, 7:549-558.
74. Alings M., Wilde A. Brugada syndrome: clinical data and suggested pathophysiological mechanism. Circulation 1999, 99:666-673.
75. + channel mutation causing both long-QT and Brugada syndromes. Circ Res 1999, 85:1206-1213.
76. Pitzalis M.V., Anaclerio M., Iacoviello M., et al. QT-interval prolongation in right precordial leads: an additional electrocardiographic hallmark of Brugada syndrome. J Am Coll Cardiol 2003, 42:1632-1637.
77. Antzelevitch C. Brugada syndrome. Pacing Clin Electrophysiol 2006, 29:1130-1159.
78. Smits J.P., Eckardt L., Probst V., et al. Genotype-phenotype relationship in Brugada syndrome: electrocardiographic features differentiate SCN5A-related patients from non-SCN5A-related patients. J Am Coll Cardiol 2002, 40:350-356.
79. Priori S.G., Gasparini M., Napolitano C., et al. Risk stratification in Brugada syndrome: results of the PRELUDE (PRogrammed ELectrical stimUlation preDictive valuE) registry. J Am Coll Cardiol 2012, 59:37-45.
80. Delise P., Allocca G., Marras E., et al. Risk stratification in individuals with the Brugada type 1 ECG pattern without previous cardiac arrest: usefulness of a combined clinical and electrophysiologic approach. Eur Heart J 2011, 32:169-176.
81. Ikeda T., Sakurada H., Sakabe K., et al. Assessment of noninvasive markers in identifying patients at risk in the Brugada syndrome: insight into risk stratification. J Am Coll Cardiol 2001, 37:1628-1634.
82. Yoshioka K., Amino M., Zareba W., et al. Identification of high-risk brugada syndrome patients by combined analysis of late potential and T-wave amplitude variability on ambulatory electrocardiograms. Circ J 2013, 77:610-618.
83. Nademanee K., Veerakul G., Chandanamattha P., et al. Prevention of ventricular fibrillation episodes in Brugada syndrome by catheter ablation over the anterior right ventricular outflow tract epicardium. Circulation 2011, 123:1270-1279.
84. Aizawa Y., Chinushi M., Tagawa M., et al. A post-QRS potential in Brugada syndrome: its relation to electrocardiographic pattern and possible genesis. J Am Coll Cardiol 2008, 51:1720-1721.
85. Furushima H., Chinushi M., Okamura K., et al. Comparison of conduction delay in the right ventricular outflow tract between Brugada syndrome and right ventricular cardiomyopathy: investigation of signal average ECG in the precordial leads. Europace 2007, 9:951-956.
86. Nagase S., Kusano K.F., Morita H., et al. Epicardial electrogram of the right ventricular outflow tract in patients with the Brugada syndrome: using the epicardial lead. J Am Coll Cardiol 2002, 39:1992-1995.
87. Huang Z., Patel C., Li W., et al. Role of signal-averaged electrocardiograms in arrhythmic risk stratification of patients with Brugada syndrome: a prospective study. Heart Rhythm 2009, 6:1156-1162.
88. Morita H., Kusano K.F., Miura D., et al. Fragmented QRS as a marker of conduction abnormality and a predictor of prognosis of Brugada syndrome. Circulation 2008, 118:1697-1704.
89. Junttila M.J., Brugada P., Hong K., et al. Differences in 12-lead electrocardiogram between symptomatic and asymptomatic Brugada syndrome patients. J Cardiovasc Electrophysiol 2008, 19:380-383.
90. Sarkozy A., Sorgente A., Boussy T., et al. The value of a family history of sudden death in patients with diagnostic type I Brugada ECG pattern. Eur Heart J 2011, 32:2153-2160.
91. Sarkozy A., Paparella G., Boussy T., et al. The usefulness of the consensus clinical diagnostic criteria in Brugada syndrome. Int J Cardiol 2013, 167:2700-2704.
92. Gehi A.K., Duong T.D., Metz L.D., Gomes J.A., Mehta D. Risk stratification of individuals with the brugada electrocardiogram: a meta-analysis. J Cardiovasc Electrophysiol 2006, 17:577-583.
93. Paul M., Gerss J., Schulze-Bahr E., et al. Role of programmed ventricular stimulation in patients with Brugada syndrome: a meta-analysis of worldwide published data. Eur Heart J 2007, 28:2126-2133.
94. Giustetto C., Drago S., Demarchi P.G., et al. Risk stratification of the patients with Brugada type electrocardiogram: a community-based prospective study. Europace 2009, 11:507-513.
95. Makimoto H., Kamakura S., Aihara N., et al. Clinical impact of the number of extrastimuli in programmed electrical stimulation in patients with Brugada type 1 electrocardiogram. Heart Rhythm 2012, 9:242-248.
96. Castro Hevia J., Antzelevitch C., Tornés Bárzaga F., et al. Tpeak-Tend and Tpeak-Tend dispersion as risk factors for ventricular tachycardia/ventricular fibrillation in patients with the Brugada syndrome. J Am Coll Cardiol 2006, 47:1828-1834.
97. Letsas K.P., Weber R., Astheimer K., Kalusche D., Arentz T. Tpeak-Tend interval and Tpeak-Tend/QT ratio as markers of ventricular tachycardia inducibility in subjects with Brugada ECG phenotype. Europace 2010, 12:271-274.
98. Karim Talib A., Sato N., Sakamoto N., et al. Enhanced transmural dispersion of repolarization in patients with J wave syndromes. J Cardiovasc Electrophysiol 2012, 23:1109-1114.
99. Lambiase P.D. Tpeak-Tend interval and Tpeak-Tend/QT ratio as markers of ventricular tachycardia inducibility in subjects with Brugada ECG phenotype. Europace 2010, 12:158-159.
100. Uzieblo-Zyczkowska B., Gielerak G., Michalkiewicz D. Usefulness of patient's history and non-invasive electrocardiographic parameters in prediction of ajmaline test results in patients with suspected Brugada syndrome. Arch Med Sci 2014, 10:899-912.
101. Wang J.F., Shan Q.J., Yang B., et al. [Tpeak-Tend interval and risk of cardiac events in patients with Brugada syndrome]. Zhonghua xin xue guan bing za zhi 2007, 35:629-632.
102. Talib A.K., Sato N., Kawabata N., et al. Repolarization characteristics in early repolarization and Brugada syndromes: insight into an overlapping mechanism of lethal arrhythmias. J Cardiovasc Electrophysiol 2014, 25:1376-1384.
103. Makimoto H., Nakagawa E., Takaki H., et al. Augmented ST-segment elevation during recovery from exercise predicts cardiac events in patients with Brugada syndrome. J Am Coll Cardiol 2010, 56:1576-1584.
104. Makimoto H., Takaki H., Doi A., et al. Clinical significance of early heart rate recovery after exercising testing in patients with Brugada syndrome. Circulation 2009, 120:S671.
105. Tatsumi H., Takagi M., Nakagawa E., Yamashita H., Yoshiyama M. Risk stratification in patients with Brugada syndrome: analysis of daily fluctuations in 12-lead electrocardiogram (ECG) and signal-averaged electrocardiogram (SAECG). J Cardiovasc Electrophysiol 2006, 17:705-711.
106. Chen Q., Kirsch G.E., Zhang D., et al. Genetic basis and molecular mechanisms for idiopathic ventricular fibrillation. Nature 1998, 392:293-296.
107. Antzelevitch C. J wave syndromes: molecular and cellular mechanisms. J Electrocardiol 2013, 46:510-518.
108. Antzelevitch C. Genetic, molecular and cellular mechanisms underlying the J wave syndromes. Circ J 2012, 76:1054-1065.
109. Kapplinger J.D., Tester D.J., Alders M., et al. An international compendium of mutations in the SCN5A encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm 2010, 7:33-46.
110. Hu D., Barajas-Martinez H., Pfeiffer R., et al. Mutations in SCN10A are responsible for a large fraction of cases of Brugada syndrome. J Am Coll Cardiol 2014, 64:66-79.
111. Weiss R., Barmada M.M., Nguyen T., et al. Clinical and molecular heterogeneity in the Brugada syndrome: a novel gene locus on chromosome 3. Circulation 2002, 105:707-713.
112. + current and causes inherited arrhythmias. Circulation 2007, 116:2260-2268.
113. Shy D., Gillet L., Abriel H. Cardiac sodium channel NaV1.5 distribution in myocytes via interacting proteins: the multiple pool model. Biochim Biophys Acta 2013, 1833:886-894.
114. Valdivia C.R., Ueda K., Ackerman M.J., Makielski J.C. GPD1L links redox state to cardiac excitability by PKC-dependent phosphorylation of the sodium channel SCN5A. Am J Physiol Heart Circ Physiol 2009, 297:H1446-H1452.
115. Watanabe H., Koopmann T.T., Le Scouarnec S., et al. Sodium channel b1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans. J ClinInvest 2008, 118:2260-2268.
116. Hu D., Barajas-Martinez H., Medeiros-Domingo A., et al. A novel rare variant in SCN1Bb linked to Brugada syndrome and SIDS by combined modulation of Na(v)1.5 and K(v)4.3 channel currents. Heart Rhythm 2012, 9:760-769.
117. Hu D., Barajas-Martinez H., Burashnikov E., et al. A mutation in the beta 3 subunit of the cardiac sodium channel associated with Brugada ECG phenotype. Circ Cardiovasc Genet 2009, 2:270-278.
118. Ishikawa T., Takahashi N., Ohno S., et al. Novel SCN3B mutation associated with Brugada syndrome affects intracellular trafficking and function of Nav1.5. Circ J 2013, 77:959-967.
119. Riuro H., Beltran-Alvarez P., Tarradas A., et al. A missense mutation in the sodium channel ß2 subunit reveals SCN2B as a new candidate gene for Brugada syndrome. Hum Mutat 2013, 34:961-966.
120. Bezzina C.R., Barc J., Mizusawa Y., et al. Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death. Nat Genet 2013, 45:1044-1049.
121. van den Boogaard M., Wong L.Y., Tessadori F., et al. Genetic variation in T-box binding element functionally affects SCN5A/SCN10A enhancer. J Clin Invest 2012, 122:2519-2530.
122. van den Boogaard M., Smemo S., Burnicka-Turek O., et al. A common genetic variant within SCN10A modulates cardiac SCN5A expression. J Clin Invest 2014, 124:1844-1852.
123. Verkerk A.O., Remme C.A., Schumacher C.A., et al. Functional Nav1.8 channels in intracardiac neurons: the link between SCN10A and cardiac electrophysiology. Circ Res 2012, 111:333-343.
124. Yang T., Atack T.C., Stroud D.M., Zhang W., Hall L., Roden D.M. Blocking Scn10a channels in heart reduces late sodium current and is antiarrhythmic. Circ Res 2012, 111:322-332.
125. Ritchie M.D., Denny J.C., Zuvich R.L., et al. Genome- and phenome-wide analyses of cardiac conduction identifies markers of arrhythmia risk. Circulation 2013, 127:1377-1385.
126. Jeff J.M., Ritchie M.D., Denny J.C., et al. Generalization of variants identified by genome-wide association studies for electrocardiographic traits in African Americans. Ann Hum Genet 2013, 77:321-332.
127. Chambers J.C., Zhao J., Terracciano C.M., et al. Genetic variation in SCN10A influences cardiac conduction. Nat Genet 2010, 42:149-152.
128. Hu D., Barajas-Martinez H., Kahlig K., et al. Genetic variants in SCN10A associated with Brugada sydrome, right bundle branch block and atrioventricular block. Heart Rhythm 2012, 9:S395.
129. Sotoodehnia N., Isaacs A., de Bakker P.I., et al. Common variants in 22 loci are associated with QRS duration and cardiac ventricular conduction. Nat Genet 2010, 42:1068-1076.
130. Boukens B.J., Sylva M., de Gier-de V.C., et al. Reduced sodium channel function unmasks residual embryonic slow conduction in the adult right ventricular outflow tract. Circ Res 2013, 113:137-141.
131. Hartman M.E., Liu Y., Zhu W.Z., et al. Myocardial deletion of transcription factor CHF1/Hey2 results in altered myocyte action potential and mild conduction system expansion but does not alter conduction system function or promote spontaneous arrhythmias. FASEB J 2014, 28:3007-3015.
132. Hennessey J.A., Marcou C.A., Wang C., et al. FGF12 is a candidate Brugada syndrome locus. Heart Rhythm 2013, 10:1886-1894.
133. Wang C., Hennessey J.A., Kirkton R.D., et al. Fibroblast growth factor homologous factor 13 regulates Na+ channels and conduction velocity in murine hearts. Circ Res 2011, 109:775-782.
134. Hennessey J.A., Wei E.Q., Pitt G.S. Fibroblast growth factor homologous factors modulate cardiac calcium channels. Circ Res 2013, 113:381-388.
135. Cerrone M., Lin X., Zhang M., et al. Missense mutations in plakophilin-2 cause sodium current deficit and associate with a Brugada syndrome phenotype. Circulation 2013, 129:1092-1103.
136. Kattygnarath D., Maugenre S., Neyroud N., et al. MOG1: a new susceptibility gene for Brugada syndrome. Circ Cardiovasc Genet 2011, 4:261-268.
137. Olesen M.S., Jensen N.F., Holst A.G., et al. A novel nonsense variant in Nav1.5 cofactor MOG1 eliminates its sodium current increasing effect and may increase the risk of arrhythmias. Can J Cardiol 2011, 27:523.
138. Ishikawa T., Sato A., Marcou C.A., et al. A novel disease gene for Brugada syndrome: sarcolemmal membrane-associated protein gene mutations impair intracellular trafficking of hNav1.5. Circ Arrhythm Electrophysiol 2012, 5:1098-1107.
139. Burashnikov E., Pfeiffer R., Barajas-Martinez H., et al. Mutations in the cardiac L-type calcium channel associated J wave sydnrome and sudden cardiac death. Heart Rhythm 2010, 7:1872-1882.
140. Cordeiro J.M., Marieb M., Pfeiffer R., Calloe K., Burashnikov E., Antzelevitch C. Accelerated inactivation of the L-type calcium due to a mutation in CACNB2b due to a mutation in CACNB2b underlies Brugada syndrome. J Mol Cell Cardiol 2009, 46:695-703.
141. Cornet V., Bichet D., Sandoz G., et al. Multiple determinants in voltage-dependent P/Q calcium channels control their retention in the endoplasmic reticulum. Eur J Neurosci 2002, 16:883-895.
142. Catterall W.A., Perez-Reyes E., Snutch T.P., Striessnig J. International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacol Rev 2005, 57:411-425.
143. Antzelevitch C., Pollevick G.D., Cordeiro J.M., et al. Loss-of-function mutations in the cardiac calcium channel underline a new clinical entity characterized by ST segment elevation, short QT intervals, and sudden cardiac death. Circ Res 2006, 99:1279.
144. 2+ channel alpha 2 delta subunit in current stimulation and subunit interaction. Neuron 1996, 16:431-440.
145. Delpón E., Cordeiro J.M., Núñez L., et al. Functional effects of KCNE3 mutation and its role in the development of Brugada syndrome. Circ Arrhythm Electrophysiol 2008, 1:209-218.
146. to) gain-of-function mutations in the KCND3-encoded Kv4.3 potassium channel and Brugada syndrome. Heart Rhythm 2011, 8:1024-1032.
147. Barajas-Martinez H., Hu D., Ferrer T., et al. Molecular genetic and functional association of Bugada and early repolarization syndromes with S422L missense mutation in KCNJ8. Heart Rhythm 2012, 9:548-555.
148. Delaney J.T., Muhammad R., Blair M.A., et al. A KCNJ8 mutation associated with early repolarization and atrial fibrillation. Europace 2012, 14:1428-1432.
149. Medeiros-Domingo A., Tan B.H., Crotti L., et al. Gain-of-function mutation S422L in the KCNJ8-encoded cardiac K(ATP) channel Kir6.1 as a pathogenic substrate for J-wave syndromes. Heart Rhythm 2010, 7:1466-1471.
150. Hu D., Barajas-Martinez H., Terzic A., et al. ABCC9 is a novel Brugada and early repolarization syndrome susceptibility gene. Int J Cardiol 2014, 171:431-442.
151. Liu H., Chatel S., Simard C., et al. Molecular genetics and functional anomalies in a series of 248 Brugada cases with 11 mutations in the TRPM4 channel. PLoS One 2013, 8:e54131.
152. Ohno S., Zankov D.P., Wei-Guang D., et al. Novel KCNE5 mutations are associated with Brugada syndrome and idiopathic ventricular fibrillation. Circulation 2009, 120:S696.
153. Itoh H., Sakaguchi T., Ashihara T., et al. A novel KCNH2 mutation as a modifier for short QT interval. Int J Cardiol 2009, 137:83-85.
154. Ueda K., Hirano Y., Higashiuesato Y., et al. Role of HCN4 channel in preventing ventricular arrhythmia. J Hum Genet 2009, 54:115-121.
155. Ueda K., Nakamura K., Hayashi T., et al. Functional characterization of a trafficking-defective HCN4 mutation, D553N, associated with cardiac arrhythmia. J Biol Chem 2004, 279:27194-27198.
156. Crotti L., Marcou C.A., Tester D.J., et al. Spectrum and prevalence of mutations Involving BrS1- through BrS12-susceptibility genes in a cohort of unrelated patients referred for Brugada syndrome genetic testing: implications for genetic testing. J Am Coll Cardiol 2012, 60:1410-1418.
157. Moosmang S., Stieber J., Zong X., Biel M., Hofmann F., Ludwig A. Cellular expression and functional characterization of four hyperpolarization-activated pacemaker channels in cardiac and neuronal tissues. Eur J Biochem 2001, 268:1646-1652.
158. Mizusawa Y., Wilde A.A. Brugada syndrome. Circ Arrhythm Electrophysiol 2012, 5:606-616.
159. Ackerman M.J., Priori S.G., Willems S., et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm 2011, 8:1308-1339.
160. Gollob M.H., Blier L., Brugada R., et al. Recommendations for the use of genetic testing in the clinical evaluation of inherited cardiac arrhythmias associated with sudden cardiac death: Canadian Cardiovascular Society/Canadian Heart Rhythm Society joint position paper. Can J Cardiol 2011, 27:232-245.
161. Szel T., Antzelevitch C. Abnormal repolarization as the basis for late potentials and fractionated electrograms recorded from epicardium in experimental models of Brugada syndrome. J Am Coll Cardiol 2014, 63:2037-2045.
162. Antzelevitch C., Sicouri S., Litovsky S.H., et al. Heterogeneity within the ventricular wall. Electrophysiology and pharmacology of epicardial, endocardial, and M cells. Circ Res 1991, 69:1427-1449.
163. Krishnan S.C., Antzelevitch C. Sodium channel block produces opposite electrophysiological effects in canine ventricular epicardium and endocardium. Circ Res 1991, 69:277-291.
164. Antzelevitch C., Brugada P., Brugada J., et al. Brugada syndrome: a decade of progress. Circ Res 2002, 91:1114-1119.
165. Krishnan S.C., Antzelevitch C. Flecainide-induced arrhythmia in canine ventricular epicardium Phase 2 reentry?. Circulation 1993, 87:562-572.
166. Antzelevitch C. The Brugada syndrome: ionic basis and arrhythmia mechanisms. J Cardiovasc Electrophysiol 2001, 12:268-272.
167. Lukas A., Antzelevitch C. Phase 2 reentry as a mechanism of initiation of circus movement reentry in canine epicardium exposed to simulated ischemia. Cardiovasc Res 1996, 32:593-603.
168. Yan G.X., Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST segment elevation. Circulation 1999, 100:1660-1666.
169. Fish J.M., Antzelevitch C. Role of sodium and calcium channel block in unmasking the Brugada syndrome. Heart Rhythm 2004, 1:210-217.
170. Kurita T., Shimizu W., Inagaki M., et al. The electrophysiologic mechanism of ST-segment elevation in Brugada syndrome. J Am Coll Cardiol 2002, 40:330-334.
171. Di Diego J.M., Cordeiro J.M., Goodrow R.J., et al. Ionic and cellular basis for the predominance of the Brugada syndrome phenotype in males. Circulation 2002, 106:2004-2011.
172. Hong K., Berruezo-Sanchez A., Poungvarin N., et al. Phenotypic characterization of a large European family with Brugada syndrome displaying a sudden unexpected death syndrome mutation in SCN5A. J Cardiovasc Electrophysiol 2004, 15:64-69.
173. Wilde A.A., Postema P.G., Di Diego J.M., et al. The pathophysiological mechanism underlying Brugada syndrome: depolarization versus repolarization. J Mol Cell Cardiol 2010, 49:543-553.
174. Morita H., Zipes D.P., Wu J. Brugada syndrome: insights of ST elevation, arrhythmogenicity, and risk stratification from experimental observations. Heart Rhythm 2009, 6:S34-S43.
175. Babaliaros V.C., Hurst J.W. Tricyclic antidepressants and the Brugada syndrome: an example of Brugada waves appearing after the administration of desipramine. Clin Cardiol 2002, 25:395-398.
176. Goldgran-Toledano D., Sideris G., Kevorkian J.P. Overdose of cyclic antidepressants and the Brugada syndrome. N Engl J Med 2002, 346:1591-1592.
177. Tada H., Sticherling C., Oral H., Morady F. Brugada syndrome mimicked by tricyclic antidepressant overdose. J Cardiovasc Electrophysiol 2001, 12:275.
178. Ortega-Carnicer J., Bertos-Polo J., Gutierrez-Tirado C. Aborted sudden death, transient Brugada pattern, and wide QRS dysrrhythmias after massive cocaine ingestion. J Electrocardiol 2001, 34:345-349.
179. Nogami A., Nakao M., Kubota S., et al. Enhancement of J-ST-segment elevation by the glucose and insulin test in Brugada syndrome. Pacing Clin Electrophysiol 2003, 26:332-337.
180. Araki T., Konno T., Itoh H., Ino H., Shimizu M. Brugada syndrome with ventricular tachycardia and fibrillation related to hypokalemia. Circ J 2003, 67:93-95.
181. Pastor A., Nunez A., Cantale C., Cosio F.G. Asymptomatic Brugada syndrome case unmasked during dimenhydrinate infusion. J Cardiovasc Electrophysiol 2001, 12:1192-1194.
182. Noda T., Shimizu W., Taguchi A., et al. ST-segment elevation and ventricular fibrillation without coronary spasm by intracoronary injection of acetylcholine and/or ergonovine maleate in patients with Brugada syndrome. J Am Coll Cardiol 2002, 40:1841-1847.
183. Kasanuki H., Ohnishi S., Ohtuka M., et al. Idiopathic ventricular fibrillation induced with vagal activity in patients without obvious heart disease. Circulation 1997, 95:2277-2285.
184. Proclemer A., Facchin D., Feruglio G.A., Nucifora R. Recurrent ventricular fibrillation, right bundle-branch block and persistent ST segment elevation in V1-V3: a new arrhythmia syndrome? A clinical case report. G Ital Cardiol 1993, 23:1211-1218.
185. Mizumaki K., Fujiki A., Tsuneda T., et al. Vagal activity modulates spontaneous augmentation of ST elevation in daily life of patients with Brugada syndrome. J Cardiovasc Electrophysiol 2004, 15:667-673.
186. Wichter T., Matheja P., Eckardt L., et al. Cardiac autonomic dysfunction in Brugada syndrome. Circulation 2002, 105:702-706.
187. Litovsky S.H., Antzelevitch C. Differences in the electrophysiological response of canine ventricular subendocardium and subepicardium to acetylcholine and isoproterenol. A direct effect of acetylcholine in ventricular myocardium. Circ Res 1990, 67:615-627.
188. Kies P., Wichter T., Schafers M., et al. Abnormal myocardial presynaptic norepinephrine recycling in patients with Brugada syndrome 1. Circulation 2004, 110:3017-3022.
189. Nimmannit S., Malasit P., Chaovakul V., Susaengrat W., Vasuvattakul S., Nilwarangkur S. Pathogenesis of sudden unexplained nocturnal death (lai tai) and endemic distal renal tubular acidosis. Lancet 1991, 338:930-932.
190. Dumaine R., Towbin J.A., Brugada P., et al. Ionic mechanisms responsible for the electrocardiographic phenotype of the Brugada syndrome are temperature dependent. Circ Res 1999, 85:803-809.
191. Gonzalez Rebollo G., Madrid H., Carcia A., Garcia de Casto A, Moro A.M. Reccurrent ventricular fibrillation during a febrile illness in a patient with the Brugada Syndrome. Rev Esp Cardiol 2000, 53:755-757.
192. Madle A., Kratochvil Z., Polivkova A. [The Brugada syndrome]. Vnitr Lek 2002, 48:255-258.
193. Saura D., Garcia-Alberola A., Carrillo P., Pascual D., Martinez-Sanchez J., Valdes M. Brugada-like electrocardiographic pattern induced by fever. Pacing Clin Electrophysiol 2002, 25:856-859.
194. Porres J.M., Brugada J., Urbistondo V., Garcia F., Reviejo K., Marco P. Fever unmasking the Brugada syndrome. Pacing Clin Electrophysiol 2002, 25:1646-1648.
195. Kum L., Fung J.W.H., Chan W.W.L., Chan G.K., Chan Y.S., Sanderson J.E. Brugada syndrome unmasked by febrile illness. Pacing Clin Electrophysiol 2002, 25:1660-1661.
196. Ortega-Carnicer J., Benezet J., Ceres F. Fever-induced ST-segment elevation and T-wave alternans in a patient with Brugada syndrome. Resuscitation 2003, 57:315-317.
197. Dzielinska Z., Bilinska Z.T., Szumowski L., et al. [Recurrent ventricular fibrillation during a febrile illness as the first manifestation of Brugada syndrome-a case report]1. Kardiol Pol 2004, 61:269-273.
198. Tanaka M., Nakamura K., Kusano K.F., et al. Elevated oxidative stress is associated with ventricular fibrillation episodes in patients with Brugada-type electrocardiogram without SCN5A mutation. Cardiovasc Pathol 2011, 20:e37-e42.
199. Brugada J., Brugada R., Brugada P. Pharmacological and device approach to therapy of inherited cardiac diseases associated with cardiac arrhythmias and sudden death. J Electrocardiol 2000, 33(suppl 41-47).
200. Brugada P., Brugada R., Brugada J., Geelen P. Use of the prophylactic implantable cardioverter defibrillator for patients with normal hearts. Am J Cardiol 1999, 83:98D-100D.
201. Takagi M., Sekiguchi Y., Yokoyama Y., Aihara N., Hiraoka M., Aonuma K. Long-term prognosis in patients with Brugada syndrome based on Class II indication for implantable cardioverter-defibrillator in the HRS/EHRA/APHRS Expert Consensus Statement: multicenter study in Japan. Heart Rhythm 2014, 11(10):1716-1720.
202. Sarkozy A., Boussy T., Kourgiannides G., et al. Long-term follow-up of primary prophylactic implantable cardioverter-defibrillator therapy in Brugada syndrome. Eur Heart J 2007, 28:334-344.
203. Rosso R., Glick A., Glikson M., et al. Outcome after implantation of cardioverter defribrillator in patients with Brugada syndrome: a multicenter Israeli study (ISRABRU). Isr Med Assoc J 2008, 10:435-439.
204. van Den Berg M.P., Wilde A.A., Viersma T.J.W., et al. Possible bradycardic mode of death and successful pacemaker treatment in a large family with features of long QT syndrome type 3 and Brugada syndrome. J Cardiovasc Electrophysiol 2001, 12:630-636.
205. Bertomeu-Gonzalez V., Ruiz-Granell R., Garcia-Civera R., Morell-Cabedo S., Ferrero A. Syncopal monomorphic ventricular tachycardia with pleomorphism, sensitive to antitachycardia pacing in a patient with Brugada syndrome. Europace 2006, 8:1048-1050.
206. Lee K.L., Lau C., Tse H., Wan S., Fan K. Prevention of ventricular fibrillation by pacing in a man with Brugada syndrome. J Cardiovasc Electrophysiol 2000, 11:935-937.
207. Ayerza M.R., de Zutter M., Goethals M., Wellens F., Geelen P., Brugada P. Heart transplantation as last resort against Brugada syndrome. J Cardiovasc Electrophysiol 2002, 13:943-944.
208. Haissaguerre M., Extramiana F., Hocini M., et al. Mapping and ablation of ventricular fibrillation associated with long-QT and Brugada syndromes. Circulation 2003, 108:925-928.
209. Nakagawa E., Takagi M., Tatsumi H., Yoshiyama M. Successful radiofrequency catheter ablation for electrical storm of ventricular fibrillation in a patient with Brugada syndrome. Circ J 2008, 72:1025-1029.
210. Shah A.J., Hocini M., Lamaison D., Sacher F., Derval N., Haissaguerre M. Regional substrate ablation abolishes Brugada syndrome. J Cardiovasc Electrophysiol 2011, 22:1290-1291.
211. Sunsaneewitayakul B., Yao Y., Thamaree S., Zhang S. Endocardial mapping and catheter ablation for ventricular fibrillation prevention in Brugada syndrome. J Cardiovasc Electrophysiol 2012, 23(suppl 1):S10-S16.
212. Cortez-Dias N., Placido R., Marta L., et al. Epicardial ablation for prevention of ventricular fibrillation in a patient with Brugada syndrome. Rev Port Cardiol 2014, 33:305.
213. Patocskai B, Szel T, Yoon N Antzelevitch C. Cellular mechanisms underlying the fractionated and late potentials on epicardial electrograms and the ameliorative effect of epicardial radiofrequency ablation in an experimental model of Brugada syndrome. In: Program and abstracts of the 24th Annual Upstate New York Cardiac Electrophysiology Society Meeting. Buffalo, NY; November 3, 2014. [Abstact 006.].
214. Chinushi M., Aizawa Y., Ogawa Y., Shiba M., Takahashi K. Discrepant drug action of disopyramide on ECG abnormalities and induction of ventricular arrhythmias in a patient with Brugada syndrome. J Electrocardiol 1997, 30:133-136.
215. Minoura Y., Di Diego J.M., Barajas-Martinez H., et al. Ionic and cellular mechanisms underlying the development of acquired Brugada syndrome in patients treated with antidepressants. J Cardiovasc Electrophysiol 2012, 23:423-432.
216. Minoura Y., Panama B.K., Nesterenko V.V., et al. Effect of Wenxin Keli and quinidine to suppress arrhythmogenesis in an experimental model of Brugada syndrome. Heart Rhythm 2013, 10:1054-1062.
217. Gurabi Z., Koncz I., Patocskai B., Nesterenko V.V., Antzelevitch C. Cellular mechanism underlying hypothermia-induced VT/VF in the setting of early repolarization and the protective effect of quinidine, cilostazol and milrinone. Circ Arrhythm Electrophysiol 2014, 7:134-142.
218. Alings M., Dekker L., Sadee A., Wilde A. Quinidine induced electrocardiographic normalization in two patients with Brugada syndrome. Pacing Clin Electrophysiol 2001, 24:1420-1422.
219. Belhassen B., Viskin S., Antzelevitch C. The Brugada syndrome: is an implantable cardioverter defibrillator the only therapeutic option?. Pacing Clin Electrophysiol 2002, 25:1634-1640.
220. Belhassen B., Viskin S. Pharmacologic approach to therapy of Brugada syndrome: quinidine as an alternative to ICD therapy?. The Brugada Syndrome: From Bench to Bedside 2004, 202-211. Blackwell Futura, Malden, MA. C. Antzelevitch, P. Brugada, J. Brugada, R. Brugada (Eds.).
221. Viskin S., Wilde A.A., Tan H.L., Antzelevitch C., Shimizu W., Belhassen B. Empiric quinidine therapy for asymptomatic Brugada syndrome: time for a prospective registry. Heart Rhythm 2009, 6:401-404.
222. Belhassen B., Glick A., Viskin S. Excellent long-term reproducibility of the electrophysiologic efficacy of quinidine in patients with idiopathic ventricular fibrillation and Brugada syndrome. Pacing Clin Electrophysiol 2009, 32:294-301.
223. Marquez M.F., Bonny A., Hernandez-Castillo E., et al. Long-term efficacy of low doses of quinidine on malignant arrhythmias in Brugada syndrome with an implantable cardioverter-defibrillator: a case series and literature review. Heart Rhythm 2013, 9:1995-2000.
224. Pellegrino P.L., Di B.M., Brunetti N.D. Quinidine for the management of electrical storm in an old patient with Brugada syndrome and syncope. Acta Cardiol 2013, 68:201-203.
225. Probst V., Evain S., Gournay V., et al. Monomorphic ventricular tachycardia due to Brugada syndrome successfully treated by hydroquinidine therapy in a 3-year-old child. J Cardiovasc Electrophysiol 2006, 17:97-100.
226. Schweizer P.A., Becker R., Katus H.A., Thomas D. Successful acute and long-term management of electrical storm in Brugada syndrome using orciprenaline and quinine/quinidine. Clin Res Cardiol 2010, 99:467-470.
227. Hasegawa K., Ashihara T., Kimura H., et al. Long-term pharmacological therapy of Brugada syndrome: is J-wave attenuation a marker of drug efficacy?. Intern Med 2014, 53:1523-1526.
228. Marquez M.F., Rivera J., Hermosillo A.G., et al. Arrhythmic storm responsive to quinidine in a patient with Brugada syndrome and vasovagal syncope. Pacing Clin Electrophysiol 2005, 28:870-873.
229. Viskin S., Antzelevitch C., Marquez M.F., Belhassen B. Quinidine: a valuable medication joins the list of 'endangered species'. Europace 2007, 12:1105-1106.
230. Ohgo T., Okamura H., Noda T., et al. Acute and chronic management in patients with Brugada syndrome associated with electrical storm of ventricular fibrillation. Heart Rhythm 2007, 4:695-700.
231. Belhassen B., Viskin S., Fish R., Glick A., Setbon I., Eldar M. Effects of electrophysiologic-guided therapy with Class IA antiarrhythmic drugs on the long-term outcome of patients with idiopathic ventricular fibrillation with or without the Brugada syndrome. J Cardiovasc Electrophysiol 1999, 10:1301-1312.
232. Hermida J.S., Denjoy I., Clerc J., et al. Hydroquinidine therapy in Brugada syndrome. J Am Coll Cardiol 2004, 43:1853-1860.
233. Mok N.S., Chan N.Y., Chi-Suen C.A. Successful use of quinidine in treatment of electrical storm in Brugada syndrome. Pacing Clin Electrophysiol 2004, 27:821-823.
234. Bouzeman A., Traulle S., Messali A., et al. Long-term follow-up of asymptomatic Brugada patients with inducible ventricular fibrillation under hydroquinidine. Europace 2014, 16:572-577.
235. Tsuchiya T., Ashikaga K., Honda T., Arita M. Prevention of ventricular fibrillation by cilostazol, an oral phosphodiesterase inhibitor, in a patient with Brugada syndrome. J Cardiovasc Electrophysiol 2002, 13:698-701.
236. Kyriazis K., Bahlmann E., van der S.H., Kuck K.H. Electrical storm in Brugada syndrome successfully treated with orciprenaline; effect of low-dose quinidine on the electrocardiogram. Europace 2009, 11:665-666.
237. Maury P., Couderc P., Delay M., Boveda S., Brugada J. Electrical storm in Brugada syndrome successfully treated using isoprenaline. Europace 2004, 6:130-133.
238. Maury P., Hocini M., Haissaguerre M. Electrical storms in Brugada syndrome: review of pharmacologic and ablative therapeutic options. Indian Pacing Electrophysiol J 2005, 5:25-34.
239. Jongman J.K., Jepkes-Bruin N., Ramdat Misier A.R., et al. Electrical storms in Brugada syndrome successfully treated with isoproterenol infusion and quinidine orally. Neth Heart J. 2007, 15:151-155.
240. Watanabe A., Fukushima K.K., Morita H., et al. Low-dose isoproterenol for repetitive ventricular arrhythmia in patients with Brugada syndrome. Eur Heart J 2006, 27:1579-1583.
241. Furniss G. Isoprenaline and quinidine to calm Brugada VF storm. BMJ Case Rep 2012, http://dx.doi.org/10.1136/bcr.04.2011.4156.
242. Suzuki H., Torigoe K., Numata O., Yazaki S. Infant case with a malignant form of Brugada syndrome. J Cardiovasc Electrophysiol 2000, 11:1277-1280.
243. Tanaka H., Kinoshita O., Uchikawa S., et al. Successful prevention of recurrent ventricular fibrillation by intravenous isoproterenol in a patient with Brugada syndrome. Pacing Clin Electrophysiol 2001, 24:1293-1294.
244. Shimizu W., Kamakura S. Catecholamines in children with congenital long QT syndrome and Brugada syndrome. J Electrocardiol 2001, 34:173-175. Suppl.
245. Sharif-Kazemi M.B., Emkanjoo Z., Tavoosi A., et al. Electrical storm in Brugada syndrome during pregnancy. Pacing Clin Electrophysiol 2011, 34:e18-e21.
246. Roten L., Derval N., Sacher F., et al. Heterogeneous response of J wave syndromes to beta-adrenergic stimulation. Heart Rhythm 2012, 9:1970-1976.
247. Kaneko Y., Horie M., Niwano S., et al. Electrical storm in patients with Brugada syndrome is associated with early repolarization. Circ Arrhythm Electrophysiol 2014, 7(6):1122-1128.
248. Agac M.T., Erkan H., Korkmaz L. Conversion of Brugada type I to type III and successful control of recurrent ventricular arrhythmia with cilostazol. Arch Cardiovasc Dis 2013, 107(8-9):476-478.
249. Kanlop N., Chattipakorn S., Chattipakorn N. Effects of cilostazol in the heart. J Cardiovasc Med (Hagerstown) 2011, 12:88-95.
250. Bai Y., Muqier, Murakami H., et al. Cilostazol protects the heart against ischaemia reperfusion injury in a rabbit model of myocardial infarction: focus on adenosine, nitric oxide and mitochondrial ATP-sensitive potassium channels. Clin Exp Pharmacol Physiol 2011, 38:658-665.
251. Shinohara T., Ebata Y., Ayabe R., et al. Combination therapy of cilostazol and bepridil suppresses recurrent ventricular fibrillation related to J-wave syndromes. Heart Rhythm 2014, 11:1441-1445.
252. Abud A., Bagattin D., Goyeneche R., Becker C. Failure of cilostazol in the prevention of ventricular fibrillation in a patient with Brugada syndrome. J Cardiovasc Electrophysiol 2006, 17:210-212.
253. Szel T., Koncz I., Antzelevitch C. Cellular mechanisms underlying the effects of milrinone and cilostazol to supress arrhythmogenesis associated with Brugada syndrome. Heart Rhythm 2013, 10:1720-1727.
254. Burashnikov A., Petroski A., Hu D., Barajas-Martinez H., Antzelevitch C. Atrial-selective inhibition of sodium channel current by Wenxin Keli is effective in suppressing atrial fibrillation. Heart Rhythm 2012, 9:125-131.
255. Wang X., Wang X., Gu Y., Wang T., Huang C. Wenxin Keli attenuates ischemia-induced ventricular arrhythmias in rats: involvement of L type calcium and transient outward potassium currents. Mol Med Rep 2013, 7:519-524.
256. Sugao M., Fujiki A., Nishida K., et al. Repolarization dynamics in patients with idiopathic ventricular fibrillation: pharmacological therapy with bepridil and disopyramide. J Cardiovasc Pharmacol 2005, 45:545-549.
257. Murakami M., Nakamura K., Kusano K.F., et al. Efficacy of low-dose bepridil for prevention of ventricular fibrillation in patients with Brugada syndrome with and without SCN5A mutation. J Cardiovasc Pharmacol 2010, 56:389-395.
258. Aizawa Y., Yamakawa H., Takatsuki S., et al. Efficacy and safety of bepridil for prevention of ICD shocks in patients with Brugada syndrome and idiopathic ventricular fibrillation. Int J Cardiol 2013, 168:5083-5085.
259. + channels as a long-term effect by blunting proteasome signals through inhibition of calmodulin activity. Br J Pharmacol 2009, 157:404-414.
260. Fish J.M., Welchons D.R., Kim Y.S., Lee S.H., Ho W.K., Antzelevitch C. Dimethyl lithospermate B, an extract of danshen, suppresses arrhythmogenesis associated with the Brugada syndrome. Circulation 2006, 113:1393-1400.
261. Antzelevitch C. The Brugada syndrome: diagnostic criteria and cellular mechanisms. Eur Heart J 2001, 22:356-363.
262. Krishnan S.C., Josephson M.E. ST segment elevation induced by class IC antiarrhythmic agents: underlying electrophysiologic mechanisms and insights into drug-induced proarrhythmia. J Cardiovasc Electrophysiol 1998, 9:1167-1172.
263. Fujiki A., Usui M., Nagasawa H., Mizumaki K., Hayashi H., Inoue H. ST segment elevation in the right precordial leads induced with class IC antiarrhythmic drugs: insight into the mechanism of Brugada syndrome. J Cardiovasc Electrophysiol 1999, 10:214-218.
264. Gasparini M., Priori S.G., Mantica M., et al. Flecainide test in Brugada syndrome: a reproducible but risky tool. Pacing Clin Electrophysiol 2003, 26:338-341.
265. Takenaka S., Emori T., Koyama S., Morita H., Fukushima K., Ohe T. Asymptomatic form of Brugada syndrome. Pacing Clin Electrophysiol 1999, 22:1261-1263.
266. Shimizu W., Aiba T., Kurita T., Kamakura S. Paradoxic abbreviation of repolarization in epicardium of the right ventricular outflow tract during augmentation of Brugada-type ST segment elevation. J Cardiovasc Electrophysiol 2001, 12:1418-1421.
267. Matana A., Goldner V., Stanic K., Mavric Z., Zaputovic L., Matana Z. Unmasking effect of propafenone on the concealed form of the Brugada phenomenon. Pacing Clin Electrophysiol 2000, 23:416-418.
268. Rolf S., Bruns H.J., Wichter T., et al. The ajmaline challenge in Brugada syndrome: diagnostic impact, safety, and recommended protocol. Eur Heart J 2003, 24:1104-1112.
269. Tada H., Nogami A., Shimizu W., et al. ST segment and T wave alternans in a patient with Brugada syndrome. Pacing Clin Electrophysiol 2000, 23:413-415.
270. Matsuo K., Shimizu W., Kurita T., Inagaki M., Aihara N., Kamakura S. Dynamic changes of 12-lead electrocardiograms in a patient with Brugada syndrome. J Cardiovasc Electrophysiol 1998, 9:508-512.
271. Bolognesi R., Tsialtas D., Vasini P., Conti M., Manca C. Abnormal ventricular repolarization mimicking myocardial infarction after heterocyclic antidepressant overdose. Am J Cardiol 1997, 79:242-245.
272. Rouleau F., Asfar P., Boulet S., et al. Transient ST segment elevation in right precordial leads induced by psychotropic drugs: relationship to the Brugada syndrome. J Cardiovasc Electrophysiol 2001, 12:61-65.
273. El-Menyar A., Khan M., Al S.J., Eljerjawy E., Asaad N. Oxcarbazepine-induced resistant ventricular fibrillation in an apparently healthy young man. Am J Emerg Med 2011, 29:693.
274. Vernooy K., Sicouri S., Dumaine R., et al. Genetic and biophysical basis for bupivacaine-induced ST segment elevation and VT/VF. Anesthesia unmasked Brugada syndrome. Heart Rhythm 2006, 3:1074-1078.
275. Phillips N., Priestley M., Denniss A.R., Uther J.B. Brugada-type electrocardiographic pattern induced by epidural bupivacaine. Anesth Analg 2003, 97:264-267. [table].
276. Arumugam D., Atherton J.J., Martin P.T. A lethal injection?. Lancet 2012, 379:492.
277. Inamura M., Okamoto H., Kuroiwa M., Hoka S. General anesthesia for patients with Brugada syndrome. A report of six cases. Can J Anaesth 2005, 52:409-412.
278. Robinson J.D., Melman Y., Walsh E.P. Cardiac conduction disturbances and ventricular tachycardia after prolonged propofol infusion in an infant. Pacing Clin Electrophysiol 2008, 31:1070-1073.
279. Vernooy K., Delhaas T., Cremer O.L., et al. Electrocardiographic changes predicting sudden death in propofol-related infusion syndrome. Heart Rhythm 2006, 3:131-137.
280. Littmann L., Monroe M.H., Svenson R.H. Brugada-type electrocardiographic pattern induced by cocaine. Mayo Clin Proc 2000, 75:845-849.
281. Romero-Puche A.J., Trigueros-Ruiz N., Cerdan-Sanchez M.C., Perez-Lorente F., Roldan D., Vicente-Vera T. Brugada electrocardiogram pattern induced by cannabis. Rev Esp Cardiol (Engl Ed) 2012, 65:856-858.
282. Brugada J., Brugada R., Brugada P. Right bundle-branch block and ST-segment elevation in leads V1 through V3. A marker for sudden death in patients without demonstrable structural heart disease. Circulation 1998, 97:457-460.
283. Fish J.M., Extramiana F., Antzelevitch C. Tedisamil abolishes the arrhythmogenic substrate responsible for VT/VF in an experimental model of the Brugada syndrome. Heart Rhythm 2004, 1:S158.
284. Fish J.M., Extramiana F., Antzelevitch C. AVE0118, an Ito and IKur blocker, suppresses VT/VF in an experimental model of the Brugada syndrome. Circulation 2004, 110:III-193.
285. Gurabi Z., Koncz I., Patocskai B., Nesterenko V.V., Antzelevitch C. Cellular mechanism underlying hypothermia-induced ventricular tachycardia/ventricular fibrillation in the setting of early repolarization and the protective effect of quinidine, cilostazol, and milrinone. Circ Arrhythm Electrophysiol 2014, 7:134-142.